

PB 88 of 2020

National Health (Weighted average disclosed price – October 2020 reduction day) Amendment Determination 2020

*National Health Act 1953*

I, THEA CONNOLLY, Assistant Secretary, Pricing and PBS Policy Branch, Department of Health, delegate of the Minister for Health, make this determination under subsection 99ADB(4) of the *National Health Act 1953*.

Dated: 9 September 2020

**THEA CONNOLLY**

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

1 Name of Instrument

 (1) This instrument is the *National Health (Weighted average disclosed price – October 2020 reduction day) Amendment Determination 2020*.

 (2) This instrument may also be cited as PB 88 of 2020.

2 Commencement

 This instrument commences on the day after it is registered.

1. Amendments to PB 54 of 2020

Schedule 1 amends the *National Health* *(Weighted average disclosed price – October 2020 reduction day) Determination 2020* (PB 54 of 2020).

**Schedule 1 Amendments**

**[1] Schedule 1**

*after:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 77 | Entecavir | Tablet 1 mg (as monohydrate) | Oral | ENTECLUDE | 117.91 |

*omit:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 78 | Epirubicin | Solution for injection containing epirubicin hydrochloride 100 mg in 50 mL | Injection/intravesical | Epirubicin ACT | 25.49 |
| 79 | Epirubicin | Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL | Injection/intravesical | Epirube | 50.98 |
| 80 | Epirubicin | Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL | Injection/intravesical | Epirubicin Accord | 50.98 |
| 81 | Epirubicin | Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL | Injection/intravesical | Epirubicin ACT | 50.98 |
| 82 | Epirubicin | Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL | Injection/intravesical | Epirube | 12.75 |
| 83 | Epirubicin | Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL | Injection/intravesical | Epirubicin ACT | 12.75 |
| 84 | Etoposide | Powder for I.V. infusion 1 g (as phosphate) | Injection | Etopophos | 342.38 |
| 85 | Etoposide | Solution for I.V. infusion 100 mg in 5 mL | Injection | Etoposide Ebewe | 34.24 |
| 86 | Etoposide | Solution for I.V. infusion 100 mg in 5 mL | Injection | Pfizer Australia Pty Ltd | 34.24 |

**[2] Schedule 1**

*after:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 228 | Zoledronic acid | Solution for I.V. infusion 4 mg (as monohydrate) in 100 mL | Injection | DBL Zoledronic Acid | 72.79 |

*omit:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 229 | Zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Aclasta | 97.45 |
| 230 | Zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Osteovan | 97.45 |
| 231 | Zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Ostira | 97.45 |
| 232 | Zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Zoledasta | 97.45 |

 *substitute:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 229 | Zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Aclasta | 97.47 |
| 230 | Zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Osteovan | 97.47 |
| 231 | Zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Ostira | 97.47 |
| 232 | Zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Zoledasta | 97.47 |

**Schedule 2 Amendments**

**[3] Schedule 2**

*after:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1,024 | Enoxaparin | Injection containing enoxaparin sodium 80 mg (8,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe | Injection | Enoxaparin Winthrop | 54.37 |

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1,024A | Epirubicin | Solution for injection containing epirubicin hydrochloride 100 mg in 50 mL | Injection/intravesical | Epirubicin ACT | 25.49 |
| 1,024B | Epirubicin | Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL | Injection/intravesical | Epirube | 50.98 |
| 1,024C | Epirubicin | Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL | Injection/intravesical | Epirubicin Accord | 50.98 |
| 1,024D | Epirubicin | Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL | Injection/intravesical | Epirubicin ACT | 50.98 |
| 1,024E | Epirubicin | Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL | Injection/intravesical | Epirube | 12.75 |
| 1,024F | Epirubicin | Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL | Injection/intravesical | Epirubicin ACT | 12.75 |

**[4] Schedule 2**

*after:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1,125 | Etoposide | Capsule 50 mg | Oral | Vepesid | 391.11 |

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1,125A | Etoposide | Powder for I.V. infusion 1 g (as phosphate) | Injection | Etopophos | 342.38 |
| 1,125B | Etoposide | Solution for I.V. infusion 100 mg in 5 mL | Injection | Etoposide Ebewe | 34.24 |
| 1,125C | Etoposide | Solution for I.V. infusion 100 mg in 5 mL | Injection | Pfizer Australia Pty Ltd | 34.24 |

 **[5] Schedule 2**

*after:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1,594 | Imipramine | Tablet containing imipramine hydrochloride 25 mg | Oral | Tofranil 25 | 7.11 |

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1,594A | Imipramine | Tablet containing imipramine hydrochloride 25 mg USP | Oral | Imipramine (Leading) | 19.00 |

**[6] Schedule 2**

*after:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1,902 | Levodopa with carbidopa | Tablet 250 mg-25 mg (USP) | Oral | Carbidopa and Levodopa Tablets, USP | 44.63 |

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1,902A | Levodopa with carbidopa and entacapone | Tablet 100 mg-25 mg (as monohydrate)-200 mg | Oral | Lecteva | 110.74 |
| 1,902B | Levodopa with carbidopa and entacapone | Tablet 100 mg-25 mg (as monohydrate)-200 mg | Oral | Carlevent | 110.74 |
| 1,902C | Levodopa with carbidopa and entacapone | Tablet 100 mg-25 mg (as monohydrate)-200 mg | Oral | Stalevo 100/25/200mg | 110.74 |
| 1,902D | Levodopa with carbidopa and entacapone | Tablet 150 mg-37.5 mg (as monohydrate)-200 mg | Oral | Lecteva | 121.22 |
| 1,902E | Levodopa with carbidopa and entacapone | Tablet 150 mg-37.5 mg (as monohydrate)-200 mg | Oral | Carlevent | 121.22 |
| 1,902F | Levodopa with carbidopa and entacapone | Tablet 150 mg-37.5 mg (as monohydrate)-200 mg | Oral | Stalevo 150/37.5/200mg | 121.22 |
| 1,902G | Levodopa with carbidopa and entacapone | Tablet 50 mg-12.5 mg (as monohydrate)-200 mg | Oral | Carlevent | 100.26 |
| 1,902H | Levodopa with carbidopa and entacapone | Tablet 50 mg-12.5 mg (as monohydrate)-200 mg | Oral | Lecteva | 100.26 |
| 1,902I | Levodopa with carbidopa and entacapone | Tablet 50 mg-12.5 mg (as monohydrate)-200 mg | Oral | Stalevo 50/12.5/200mg | 100.26 |
| 1,902J | Levodopa with carbidopa and entacapone | Tablet 125 mg-31.25 mg (as monohydrate)-200 mg | Oral | Lecteva | 114.94 |
| 1,902K | Levodopa with carbidopa and entacapone | Tablet 125 mg-31.25 mg (as monohydrate)-200 mg | Oral | Stalevo 125/31.25/200mg | 114.94 |
| 1,902L | Levodopa with carbidopa and entacapone | Tablet 125 mg-31.25 mg (as monohydrate)-200 mg | Oral | Carlevent | 114.94 |
| 1,902M | Levodopa with carbidopa and entacapone | Tablet 200 mg-50 mg (as monohydrate)-200 mg | Oral | Carlevent | 130.86 |
| 1,902N | Levodopa with carbidopa and entacapone | Tablet 200 mg-50 mg (as monohydrate)-200 mg | Oral | Stalevo 200/50/200mg | 130.86 |
| 1,902O | Levodopa with carbidopa and entacapone | Tablet 200 mg-50 mg (as monohydrate)-200 mg | Oral | Lecteva | 130.86 |
| 1,902P | Levodopa with carbidopa and entacapone | Tablet 75 mg-18.75 mg (as monohydrate)-200 mg | Oral | Lecteva | 104.87 |
| 1,902Q | Levodopa with carbidopa and entacapone | Tablet 75 mg-18.75 mg (as monohydrate)-200 mg | Oral | Carlevent | 104.87 |
| 1,902R | Levodopa with carbidopa and entacapone | Tablet 75 mg-18.75 mg (as monohydrate)-200 mg | Oral | Stalevo 75/18.75/200mg | 104.87 |

**[7] Schedule 2**

*after:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1,954 | Losartan | Tablet containing losartan potassium 50 mg | Oral | Cozavan | 7.25 |

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1,954A | Lurasidone | Tablet containing lurasidone hydrochloride 40 mg | Oral | Lurasidone Lupin | 46.48 |
| 1,954B | Lurasidone | Tablet containing lurasidone hydrochloride 40 mg | Oral | Ardix Lurasidone | 46.48 |
| 1,954C | Lurasidone | Tablet containing lurasidone hydrochloride 40 mg | Oral | Latuda | 46.48 |
| 1,954D | Lurasidone | Tablet containing lurasidone hydrochloride 80 mg | Oral | Latuda | 92.96 |
| 1,954E | Lurasidone | Tablet containing lurasidone hydrochloride 80 mg | Oral | Ardix Lurasidone | 92.96 |
| 1,954F | Lurasidone | Tablet containing lurasidone hydrochloride 80 mg | Oral | Lurasidone Lupin | 92.96 |

**[8] Schedule 2**

*after:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 2,035 | Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | Metformin XR 500 APOTEX | 3.72 |

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 2.035A | Metformin | Tablet (prolonged release) containing metformin hydrochloride 500 mg | Oral | Metformin (Medsurge) | 4.01 |

**[9] Schedule 2**

*after:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 2,096 | Methylphenidate | Capsule containing methylphenidate hydrochloride 40 mg (modified release) | Oral | Ritalin LA | 38.07 |

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 2,096A | Methylphenidate | Capsule containing methylphenidate hydrochloride 60 mg (modified release) | Oral | Ritalin LA | 51.01 |

**[10] Schedule 2**

*after:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 2,367 | Nitrazepam | Tablet 5 mg | Oral | Mogadon | 1.48 |

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 2,367A | Nitrofurantoin | Capsule 100 mg | Oral | APO-Nitrofurantoin | 14.67 |
| 2,367B | Nitrofurantoin | Capsule 100 mg | Oral | Macrodantin | 14.67 |
| 2,367C | Nitrofurantoin | Capsule 50 mg | Oral | Macrodantin | 10.46 |
| 2,367D | Nitrofurantoin | Capsule 50 mg | Oral | APO-Nitrofurantoin | 10.46 |

**[11] Schedule 2**

*after:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 3,224 | Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation) | Inhalation by mouth | Ventolin CFC-free | 3.88 |

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 3,224A | Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by Mouth | Zempreon CFC-Free with dose counter | 4.49 |
| 3,224B | Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by Mouth | Ventolin CFC-Free with dose counter | 4.49 |